![]() | Only 14 pages are availabe for public view |
Abstract Background: Fetal growth restriction is a major obstetrical problem, which represents a main cause of perinatal morbidity and mortality; it is defined as a fetal weight below the 10th percentile for gestational age or more specifically failure of a fetus to reach its genetically determined growth potential for pathological causes. It affects approximately 3 to 7% of all pregnancies. Aim of the work: The aim of this study is to assess the effect of Sildenafil citrate therapy on neonatal outcomes in women with FGR. Patients and Methods: This prospective, double-blind, randomized, placebo-controlled clinical trial was conducted at Ain Shams University Maternity Hospital on Sixty Pregnant women with FGR and color Doppler velocimetry changes in the umbilical artery, in the period from April 2017 to December 2017 after approval of the Research and Ethics Committee of Ain Shams University Maternity Hospital, Cairo, Egypt in accordance with local research governance requirements. Results: The Sildenafil citrate group showed a statistically significant decrease in the umbilical artery resistance index (mean ± SD 0.09 ± 0.02), with a statistically significant increase in the fetal weight progress during pregnancy (76.0 ± 34.4) g/week and fetal gestational age at delivery (35.9 ± 0.7) weeks. But there was no statistically significant difference in the maternal side effects except for vertigo and flushing with a significant decrease in the maternal SBP and DBP. Conclusion: Sildenafil citrate has an effective role in the improvement of neonatal outcome in cases of FGR as regards umbilical artery Doppler indices, fetal weight progress during pregnancy and gestational age at delivery. Recommendations: Its usage with subcutaneous heparin is more effective than the use of heparin only. Administration of sildenafil citrate as empirical drug in the cases of FGR, as it improves the fetal outcomes and Doppler indices and has mild side effects. |